ArticleTransplantation and cellular therapy2025

Out-of-Pocket Expenditures and Financial Hardship Among Patients With Myelodysplastic Syndrome Undergoing Allogeneic Transplant or Hypomethylating Agent / Supportive Care (BMT CTN 1102).

Christopher T Su et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.